Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102.

Kasi, P M; Grothey, A

Kasi, P M; Grothey, A.

Afiliação

Kasi PM; Division of Hematology, Oncology and Bone Marrow Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
Grothey A; West Cancer Center and Research Institute, OneOncology, Germantown, Tennessee, USA. Electronic address: agrothey@westclinic.com.

Ann Oncol ; 31(1): 15-16, 2020 01.

Article em En | MEDLINE | ID: mdl-31912790

Assuntos

Neoplasias Colorretais; Neutropenia; Combinação de Medicamentos; Humanos; Pirrolidinas; Timina; Trifluridina; Uracila/análogos & derivados

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Neutropenia Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google